BioShanghai Week 2026
BioShanghai Week 2026 (or Shanghai International Biopharma Industry Week) will be held September 17–20, 2026 at Zhangjiang Science Hall, Shanghai. Since its sixth edition, BioShanghai Week has become a iconic platform for biopharmaceutical innovation and…
CPHI & PMEC Shenzhen 2026
China is the world’s 2nd largest pharma market, which is valued at USD 282.07bn in 2024, and projected to reach USD 402bn by 2029. AI in pharma is surging at 41.52% CAGR, the fastest across all sectors. Why Shenzhen? Shenzhen’s 1,300+ biotech…
Clinical Trial Supply China 2026
Clinical Trial Supply China is returning for a second year! This is your gateway to understanding and excelling in the rapidly evolving landscape of clinical trial logistics in China. Why attend? Navigate Local Challenges: Gain critical insights into the…
CBI 2026 – Antibody Drug Development Conference
Bispecific antibody deal volumes continue to hit record highs, as the battlefield for antibody therapeutics rapidly expands from oncology into multi-billion-dollar markets such as autoimmune diseases, chronic conditions, and cardiovascular disorders.…
CBI 2026 – XDC Drug Development Conference
Currently, antibody-drug conjugates (ADCs) have entered a critical phase characterized by intensive clinical advancement and commercialization. Meanwhile, emerging technological platforms such as peptide-drug conjugates (PDCs) and radionuclide-conjugated…
China Medicine Connect Expo 2026
China Medicine Connect Expo 2026 is a large pharmaceutical/biotech industry event covering innovative drugs, biologics, CGT, ADC/XDC, peptides, CMC, manufacturing and partnering. Organizers expect 800+ pharma companies and substantial…
Biokin’s Iza-Bren Hits Phase 3 PFS Endpoint in HR+/HER2− Breast Cancer, Marking 5th Phase 3 Success
Biokin Pharmaceutical’s first-in-class EGFR×HER3 bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren; BL-B01D1) has delivered another positive Phase 3 readout, meeting the progression-free survival endpoint in previously treated…
Akeso’s Ivonescimab Beats Durvalumab Standard in Phase 3 Biliary Tract Cancer Trial
Akeso’s PD-1/VEGF bispecific antibody ivonescimab has delivered another major Phase 3 victory, this time outside lung cancer, demonstrating a statistically significant overall survival advantage over durvalumab plus chemotherapy in first-line advanced…
China’s NMPA Conditionally Approves GenrixBio’s Velinotamig for Heavily Pretreated Multiple Myeloma
China’s National Medical Products Administration (NMPA) has granted conditional approval to velinotamig (GR1803), a BCMA×CD3 bispecific antibody developed by Genrix Bio and partnered with Fosun Pharma’s YaoPharma, for adults with heavily pretreated…
BRL Medicine’s BRL-101 Meets Primary Endpoint in Pivotal Trial for Transfusion-Dependent β-Thalassemia
BRL Medicine’s gene-edited stem cell therapy BRL-101 has met the prespecified primary efficacy endpoint in a pivotal Chinese study for transfusion-dependent β-thalassemia, with all 30 treated patients achieving transfusion independence and the…